Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AC Immune (ACIU) EBT: 2015-2025

Historic EBT for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -$19.8 million.

  • AC Immune's EBT fell 412.11% to -$19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.6 million, marking a year-over-year decrease of 89.60%. This contributed to the annual value of -$58.1 million for FY2024, which is 4.92% up from last year.
  • Latest data reveals that AC Immune reported EBT of -$19.8 million as of Q3 2025, which was up 22.55% from -$25.6 million recorded in Q2 2025.
  • Over the past 5 years, AC Immune's EBT peaked at $6.4 million during Q3 2024, and registered a low of -$25.6 million during Q2 2025.
  • For the 3-year period, AC Immune's EBT averaged around -$16.7 million, with its median value being -$18.9 million (2023).
  • Its EBT has fluctuated over the past 5 years, first soared by 137.06% in 2024, then crashed by 412.11% in 2025.
  • Over the past 5 years, AC Immune's EBT (Quarterly) stood at -$23.1 million in 2021, then rose by 15.65% to -$19.5 million in 2022, then surged by 72.52% to -$5.3 million in 2023, then tumbled by 237.18% to -$18.0 million in 2024, then plummeted by 412.11% to -$19.8 million in 2025.
  • Its EBT stands at -$19.8 million for Q3 2025, versus -$25.6 million for Q2 2025 and -$21.2 million for Q1 2025.